^
    17h
    Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2029 --> Mar 2031 | Trial primary completion date: Dec 2029 --> Mar 2028 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • oxaliplatin • irinotecan • leucovorin calcium • Visudyne (verteporfin) • fluorouracil topical
    21h
    Integrin α6-targeted photodynamic therapy potentiates PD-1 blockade in MSS colorectal cancer. (PubMed, J Nanobiotechnology)
    In vivo fluorescence imaging demonstrated enhanced tumor accumulation and prolonged retention of Ce6-RWYD compared with the talaporfin sodium (NPe6)...Combination with anti-PD-1 further enhanced antitumor efficacy, accompanied by increased intratumoral CD8⁺ T-cell infiltration and reduced Gr-1⁺ myeloid cells. Collectively, these findings demonstrate that Ce6-RWYD-mediated PDT sensitizes MSS colorectal cancer to PD-1 blockade.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Litx (talaporfin)
    6d
    Folate-Targeted Liposomal Delivery of a Ru(II)-Based Photosensitizer for Photodynamic Tumor Therapy via Pyroptosis Induction. (PubMed, Adv Healthc Mater)
    Mechanistic investigations demonstrated that light-triggered reactive oxygen species generation activates the caspase-3/GSDME-mediated pyroptosis pathway. This study demonstrated a rationally designed, targeted nanoplatform that utilizes a multifunctional Ru(II)-based photosensitizer and induces pyroptosis, providing a viable approach to improve the efficacy of tumor photodynamic therapy.
    Journal
    |
    CASP3 (Caspase 3) • GSDME (Gasdermin E)
    8d
    RANBP1 promotes oral cancer progression through activating YAP1 and NDUFB3 derived from the database of single-cell sequencing. (PubMed, Cancer Cell Int)
    Increased NDUFB3 expression in RANBP1-overexpressing cells was reversed by YAP1 inhibitor verteporfin treatment or knocking down YAP1. RANBP1 enhances a more invasive microenvironment of OSCC.
    Journal
    |
    YAP1 (Yes associated protein 1)
    |
    Visudyne (verteporfin)
    17d
    PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure (clinicaltrials.gov)
    P2, N=112, Not yet recruiting, Therakos LLC
    New P2 trial • Checkpoint inhibition
    |
    Entyvio (vedolizumab)
    28d
    Phase I Study in Advanced Malignancies With 5-ALA (clinicaltrials.gov)
    P1, N=130, Suspended, Fox Chase Cancer Center | Trial completion date: Feb 2027 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    1m
    Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 discriminates AGS and MKN45 cells of human gastric cancer. (PubMed, Gastroenterol Hepatol Bed Bench)
    The significantly differentially expressed genes (DEGs) from the Gene Expression Omnibus (GEO) database, which discriminate AGS and MKN45 cells in the presence of DMSO and verteporfin (a chemotherapy reagent), are determined...MKN45 was highlighted as more invasive cancer cell relative to AGS cells. PLOD2 was pointed out as a suitable target in the chemotherapy of gastric cancer.
    Journal
    |
    PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2)
    |
    Visudyne (verteporfin)
    1m
    CAF-derived exosomes drive trastuzumab resistance in HER2-positive breast cancer via YAP-USP8-HER2 axis activation. (PubMed, Breast Cancer Res)
    This study identified a novel CAF-exosome-YAP-USP8-HER2 signaling axis that drives trastuzumab insensitivity in HER2-positive breast cancer. Intervening in this pathway may represent a potential treatment approach to counteract microenvironment-induced chemoresistance.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset) • YAP1 (Yes associated protein 1) • LATS1 (Large Tumor Suppressor Kinase 1)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Visudyne (verteporfin)
    1m
    Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=19, Completed, Roswell Park Cancer Institute | Terminated --> Completed
    Trial completion
    |
    Photofrin (porfimer sodium)
    1m
    SCARFREE-001: Verteporfin for Scar Prevention (2025-525083-14-00)
    P1/2, N=12, Not yet recruiting, Odense University Hospital
    New P1/2 trial
    |
    Visudyne (verteporfin)
    1m
    The clinical ionizable lipid SM-102 enhances photochemical immunogenic cell death by verteporfin-conjugated liposomes and improves survival in vivo. (PubMed, Photochem Photobiol Sci)
    In an immune-cold syngeneic mouse PDAC model, 690 nm light activation of SM-102-containing liposomes slowed tumor growth by up to 56% and extended survival by 40%. Together, these findings suggest that integrating SM-102 into light-activated liposomes is a simple and robust strategy to enhance photochemical ICD and may improve therapeutic outcomes in immunotherapy-based combinations that utilize liposomal drug delivery systems.
    Preclinical • Journal
    |
    HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
    |
    Visudyne (verteporfin)
    2ms
    PHOTAC: Photodynamic Therapy With Topical Application of a Zn(II) Phthalocyanine (RLP068/Cl) and Red Light for the Treatment of Moderate-to-severe Acne Vulgaris (clinicaltrials.gov)
    P=N/A, N=10, Not yet recruiting, Università degli Studi di Brescia | Trial completion date: Dec 2025 --> Apr 2027 | Initiation date: Jul 2025 --> Aug 2026 | Trial primary completion date: Oct 2025 --> Dec 2026
    Trial completion date • Trial initiation date • Trial primary completion date